Developer docs
API playgroundTry for free, no card

Search company profiles

Synergy Pharmaceuticals

Full company profile

uuid0005nmn

Namestring
Synergy Pharmaceuticals
Websiteurl
synergypharma.com
Company typeenum
Private
Founded yearint
1992
Descriptiontext

Synergy Pharmaceuticals was a biopharmaceutical company developing novel therapies for the treatment of gastrointestinal conditions. Founded in 1992 and headquartered in New York, the company was publicly traded on NASDAQ under the ticker symbol SGYP. It operated with a headcount in the 251-500 range and maintained a leadership team that included Kunwar Shailubhai as Chief Scientific Officer. The company's core focus was on developing therapeutics for gastrointestinal disorders, and it is referenced as a participant in the broader medical affairs outsourcing market, which was projected to grow at a 12.5% CAGR through 2032.

The company financed its operations through multiple capital raises, including a $300 million round led by CRG in September 2017 and an $89.8 million round in May 2016, alongside earlier financings from 2009 through 2014 involving investors such as Aisling Capital. Despite raising over $400 million cumulatively, the company reported deeply negative operating results across every reported year from 2013 through 2017, with operating losses compounding annually and culminating in massive net losses by 2017. The company did not achieve sustained profitability or meaningful revenue scale during its operating period.

The company appears to no longer be operating as an active enterprise. Its website, synergypharma.com, is currently a parked domain hosted by GoDaddy, with no active web presence, product portfolio, or investor relations content accessible. No current management, contact details, or operating geographies are available, and the firmographics data carries no recent operational signals. This strongly suggests the company has been dissolved, acquired without a successor entity, or otherwise ceased independent operations.

Ownership categoryenum
Headcount rangeband
251–500
akta.pro rankint
HeadquartersNew York, United States
HQ citystring
New York
HQ countrystring
United States
HQ regionstring
North America
Markets served

Serves global market

Keyword5 values
gastrointestinal therapeutics, chronic constipation treatment, IBS-C therapies, biopharmaceutical drug development, guanylate cyclase agonists
Industry1 code
1Gastroenterology Specialty Pharmaceuticals
CodeHLAIACAEPrimaryYes
NAICS code2 codes
  • Pharmaceutical Preparation Manufacturing325412
  • Scientific Research and Development Services5417
SIC code1 code
  • Pharmaceutical Preparations2834
Product category
Gastrointestinal Therapeutics
Cost components5 values
Technology or R&D, Personnel, Operations, Marketing or Sales, Supply Chain
GTM typeB2B
B2B
Offering typeHardware or Manufacturing
Hardware or Manufacturing
Core offering1 text field

Synergy Pharmaceuticals is a biopharmaceutical company developing novel therapies for the treatment of gastrointestinal conditions. Its core offering centers on proprietary drug development targeting chronic idiopathic constipation, irritable bowel syndrome with constipation (IBS-C), and related functional GI disorders. The company participates in the medical affairs outsourcing market as a key player, leveraging its specialized GI therapeutics pipeline and scientific capabilities.

Differentiator
Functional benefit
Problem solved
Product overview1 text field

No specific product or service information is available in the provided sources. The company's website (synergypharma.com) is currently parked and inactive, indicating no active product portfolio information is accessible. The news sources reference market trends in pharmaceutical sectors (medical affairs outsourcing and oral protein/peptides markets) but do not provide details about Synergy Pharmaceuticals' specific product offerings.

Product and service2 records
1Novel gastrointestinal therapies (GI conditions pipeline)
CategoryGastrointestinal Therapeutics
Description

Novel therapies for the treatment of gastrointestinal conditions including chronic idiopathic constipation and IBS-C, developed as prescription therapeutics for healthcare providers and patients with functional GI disorders.

2Medical affairs outsourcing services
CategoryMedical Affairs Outsourcing
Description

Medical affairs outsourcing solutions for the pharmaceutical industry, leveraging the company's specialized gastrointestinal therapeutics expertise to serve pharmaceutical sponsor clients.

Scale indicator1 record

Each record includes

Type, Value, Description, Source

Recent move4 records

Each record includes

Date, Type, Title, Description, Source

Expansion highlight2 records

Each record includes

Type, Description

Peers10 records
1Ardelyx
TypeDirect peer
Description

Specialty biopharma commercializing GI products (e.g., IBSRELA, XPHMAH/XPHOZAH for hyperphosphatemia in CKD). Comparable as a GI-focused specialty pharma with similar commercialization profile.

2Takeda Pharmaceutical
TypeBroad incumbent
Description

Global pharma with significant gastroenterology presence (e.g., Entyvio for IBD). Broad incumbent competing in the same GI therapeutic categories.

3Sebela Pharmaceuticals
TypeEmerging player
Description

Private specialty pharma focused on gastroenterology and women's health. Similar therapeutic focus with a smaller commercial footprint, comparable as a GI specialty peer.

4Phathom Pharmaceuticals
TypeEmerging player
Description

Specialty biopharma commercializing GI products (e.g., Voquezna for H. pylori and erosive GERD). Comparable small-cap GI specialty commercial peer.

5AbbVie (Allergan)
TypeBroad incumbent
Description

Large incumbent pharma with an established GI franchise (e.g., Linzess, via collaboration). Comparable as a broader gastroenterology competitor and potential acquirer/partner.

6RedHill Biopharma
TypeDirect peer
Description

Specialty pharma with a GI-dominated commercial portfolio (e.g., Talicia, Aemcolo, Movantik). Closely comparable specialty-GI commercial peer.

7Intercept Pharmaceuticals
TypeEmerging player
Description

Biopharma focused on liver and GI diseases, including Ocaliva for primary biliary cholangitis. Comparable as a specialty biopharma in adjacent hepatology/GI therapeutic areas.

8Ironwood Pharmaceuticals (Cyclerion)
TypeDirect peer
Description

Specialty GI biopharmaceutical company with a comparable gastroenterology focus (e.g., linaclotide franchise). Direct therapeutic-area and commercial-model peer for Synergy's GI pipeline.

9Bausch Health (Salix Pharmaceuticals)
TypeDirect peer
Description

GI specialty pharma franchise (Salix) with products overlapping Synergy's gastroenterology focus. Direct therapeutic-area peer in marketing branded Rx GI products to gastroenterologists.

10Pfizer (GI Franchise)
TypeBroad incumbent
Description

Mega-cap pharma with historical GI assets (e.g., gastroenterology partner of Ironwood). Relevant broad incumbent in the GI specialty space.

Market position
Strengths4 records

Each record includes

Headline, Details, Source

Weaknesses4 records

Each record includes

Headline, Details, Source

Competitive moat3 records

Each record includes

Type, Details

Key risks4 records

Each record includes

Headline, Details, Source

Key highlights5 records

Each record includes

Headline, Details, Source

Customer concentration

Classification, Details

Ideal customer profile1 record

Each record includes

Profile, Firmographic size, Sales motion, Sales cycle length, Buying structure, Purchase trigger, Buyer persona, Geography, Industry vertical, Primary use case, Description, Pain points, Evidence proof points, Target buyer

Technology focused
Yes
API detail
Has APIbool
No

Docs URL, Description

AI maturity
App detail

Has app

Core technology
Revenue estimate
Valuation estimate
Number of profiles
Profiles1 record

Each record includes

Name, Designation, Designation category, Overview, Profile commentary, Source

No data
No data
Funding overview

Funding stage, Last funding date, Total funding USD

Funding rounds6 records

Each record includes

Round, Amount USD, Date, Pre money valuation, Total investors, Investors, News

Investors2 records

Each record includes

Name, Type, Date of entry, Rounds participated, Website

Funding detail is available on the Subscription and Enterprise plan.Contact sales →

M&A

Each record includes

Name, Acquisition type, Announced date, Completed date, Status, Website, News

Investment

Each record includes

Name, Round, Announced date, Lead investor, Website, News

M&A and investment is available on the Subscription and Enterprise plan.Contact sales →

Synergy Pharmaceuticals

Gastrointestinal Therapeuticssynergypharma.com

What Synergy Pharmaceuticals does

Synergy Pharmaceuticals was a biopharmaceutical company developing novel therapies for the treatment of gastrointestinal conditions. Founded in 1992 and headquartered in New York, the company was publicly traded on NASDAQ under the ticker symbol SGYP. It operated with a headcount in the 251-500 range and maintained a leadership team that included Kunwar Shailubhai as Chief Scientific Officer. The company's core focus was on developing therapeutics for gastrointestinal disorders, and it is referenced as a participant in the broader medical affairs outsourcing market, which was projected to grow at a 12.5% CAGR through 2032.

The company financed its operations through multiple capital raises, including a $300 million round led by CRG in September 2017 and an $89.8 million round in May 2016, alongside earlier financings from 2009 through 2014 involving investors such as Aisling Capital. Despite raising over $400 million cumulatively, the company reported deeply negative operating results across every reported year from 2013 through 2017, with operating losses compounding annually and culminating in massive net losses by 2017. The company did not achieve sustained profitability or meaningful revenue scale during its operating period.

The company appears to no longer be operating as an active enterprise. Its website, synergypharma.com, is currently a parked domain hosted by GoDaddy, with no active web presence, product portfolio, or investor relations content accessible. No current management, contact details, or operating geographies are available, and the firmographics data carries no recent operational signals. This strongly suggests the company has been dissolved, acquired without a successor entity, or otherwise ceased independent operations.

Synergy Pharmaceuticals firmographics

Firmographics
Name
Synergy Pharmaceuticals
Website
https://synergypharma.com
Company type
Private
Founded year
1992
Headcount range
251–500 employees
Ownership category
akta.pro rank

Synergy Pharmaceuticals industry classification

Industry
Product category
Gastrointestinal Therapeutics
NAICS
Pharmaceutical Preparation Manufacturing (325412), Scientific Research and Development Services (5417)
SIC
Pharmaceutical Preparations (2834)
akta.pro primary industry
Gastroenterology Specialty Pharmaceuticals (HLAIACAE)

Keywords

  • Gastrointestinal therapeutics
  • Chronic constipation treatment
  • IBS-C therapies
  • Biopharmaceutical drug development
  • Guanylate cyclase agonists

Where Synergy Pharmaceuticals is headquartered

Location

Headquarters

HQ city
New York
HQ country
United States
HQ region
North America

Markets served

Synergy Pharmaceuticals business model

Business model
GTM type
B2B
Offering type
Hardware or Manufacturing
Cost components
Technology or R&D, Personnel, Operations, Marketing or Sales, Supply Chain

Synergy Pharmaceuticals product offering

Product offering

Core offering

Synergy Pharmaceuticals is a biopharmaceutical company developing novel therapies for the treatment of gastrointestinal conditions. Its core offering centers on proprietary drug development targeting chronic idiopathic constipation, irritable bowel syndrome with constipation (IBS-C), and related functional GI disorders. The company participates in the medical affairs outsourcing market as a key player, leveraging its specialized GI therapeutics pipeline and scientific capabilities.

Product overview

No specific product or service information is available in the provided sources. The company's website (synergypharma.com) is currently parked and inactive, indicating no active product portfolio information is accessible. The news sources reference market trends in pharmaceutical sectors (medical affairs outsourcing and oral protein/peptides markets) but do not provide details about Synergy Pharmaceuticals' specific product offerings.

Differentiator

Problem solved

Functional benefit

Products and services

  • Novel gastrointestinal therapies (GI conditions pipeline) Novel therapies for the treatment of gastrointestinal conditions including chronic idiopathic constipation and IBS-C, developed as prescription therapeutics for healthcare providers and patients with functional GI disorders.
  • Medical affairs outsourcing services Medical affairs outsourcing solutions for the pharmaceutical industry, leveraging the company's specialized gastrointestinal therapeutics expertise to serve pharmaceutical sponsor clients.

Companies that use Synergy Pharmaceuticals

Customer profile

Ideal customer profiles1 record

Synergy Pharmaceuticals technology and API

Technology

Technology focussed Yes

API detail

Has API
No
API docs
API detail

Core technology

AI maturity

App detail

Synergy Pharmaceuticals partnerships and signals

Strategic signal

Scale indicators1 record

Recent moves4 records

Expansion highlights2 records

Synergy Pharmaceuticals competitors and assessment

Company assessment

Direct peers

  • Ardelyx: Specialty biopharma commercializing GI products (e.g., IBSRELA, XPHMAH/XPHOZAH for hyperphosphatemia in CKD). Comparable as a GI-focused specialty pharma with similar commercialization profile.
  • RedHill Biopharma: Specialty pharma with a GI-dominated commercial portfolio (e.g., Talicia, Aemcolo, Movantik). Closely comparable specialty-GI commercial peer.
  • Ironwood Pharmaceuticals (Cyclerion): Specialty GI biopharmaceutical company with a comparable gastroenterology focus (e.g., linaclotide franchise). Direct therapeutic-area and commercial-model peer for Synergy's GI pipeline.
  • Bausch Health (Salix Pharmaceuticals): GI specialty pharma franchise (Salix) with products overlapping Synergy's gastroenterology focus. Direct therapeutic-area peer in marketing branded Rx GI products to gastroenterologists.

Broad incumbents

  • Takeda Pharmaceutical: Global pharma with significant gastroenterology presence (e.g., Entyvio for IBD). Broad incumbent competing in the same GI therapeutic categories.
  • AbbVie (Allergan): Large incumbent pharma with an established GI franchise (e.g., Linzess, via collaboration). Comparable as a broader gastroenterology competitor and potential acquirer/partner.
  • Pfizer (GI Franchise): Mega-cap pharma with historical GI assets (e.g., gastroenterology partner of Ironwood). Relevant broad incumbent in the GI specialty space.

Emerging players

  • Sebela Pharmaceuticals: Private specialty pharma focused on gastroenterology and women's health. Similar therapeutic focus with a smaller commercial footprint, comparable as a GI specialty peer.
  • Phathom Pharmaceuticals: Specialty biopharma commercializing GI products (e.g., Voquezna for H. pylori and erosive GERD). Comparable small-cap GI specialty commercial peer.
  • Intercept Pharmaceuticals: Biopharma focused on liver and GI diseases, including Ocaliva for primary biliary cholangitis. Comparable as a specialty biopharma in adjacent hepatology/GI therapeutic areas.

Market position

Strengths4 records

Weaknesses4 records

Competitive moat3 records

Key risks4 records

Key highlights5 records

Customer concentration

Synergy Pharmaceuticals social profiles

Digital presence

Synergy Pharmaceuticals financial estimates

Financial estimate

Revenue estimate

Valuation estimate

Synergy Pharmaceuticals leadership team

Management profile

Number of profiles

Profiles1 record

Synergy Pharmaceuticals funding detail

Funding detail

Funding overview

Funding rounds6 records

Investors2 records

Funding detail is available on the Subscription and Enterprise plan.Contact sales →

Synergy Pharmaceuticals M&A and investment

M&A and investment

M&A

Investments

M&A and investment is available on the Subscription and Enterprise plan.Contact sales →

Frequently asked questions about Synergy Pharmaceuticals

What does Synergy Pharmaceuticals do?

Synergy Pharmaceuticals is a biopharmaceutical company developing novel therapies for the treatment of gastrointestinal conditions. Its core offering centers on proprietary drug development targeting chronic idiopathic constipation, irritable bowel syndrome with constipation (IBS-C), and related functional GI disorders. The company participates in the medical affairs outsourcing market as a key player, leveraging its specialized GI therapeutics pipeline and scientific capabilities.

When was Synergy Pharmaceuticals founded?

Synergy Pharmaceuticals was founded in 1992. It employs 251 to 500 people.

Where is Synergy Pharmaceuticals based?

Synergy Pharmaceuticals is headquartered in New York, United States, in the North America region.

Who are Synergy Pharmaceuticals's main competitors?

Direct peers on record are Ardelyx, RedHill Biopharma, Ironwood Pharmaceuticals (Cyclerion) and Bausch Health (Salix Pharmaceuticals). Broad incumbents are Takeda Pharmaceutical, AbbVie (Allergan) and Pfizer (GI Franchise). Emerging players are Sebela Pharmaceuticals, Phathom Pharmaceuticals and Intercept Pharmaceuticals.

Does Synergy Pharmaceuticals have an API?

No public API is recorded for Synergy Pharmaceuticals.

What industry is Synergy Pharmaceuticals in?

Synergy Pharmaceuticals's product category is Gastrointestinal Therapeutics. Its primary akta.pro industry code is HLAIACAE, Gastroenterology Specialty Pharmaceuticals. Its NAICS code is 325412 and its SIC code is 2834.

Unlock the full company data

50 free credits on sign-up, no credit card required.

Contact sales
Live signals
PR NewswireNew Therapeutic Outlook to Treat Irritable Bowel Syndrome is expected to generate Sales to US$ 7.2 Bn Through 2031Persistence Market Research released a market analysis projecting the global irritable bowel syndrome treatment market to reach US$ 7.2 billion by 2031, growing at a CAGR of 8.7% from a 2020 valuation of US$ 2.9 billion, driven by rising prevalence of gastrointestinal disorders and increased government engagement. Key strategic developments include Bausch Health's acquisition of Synergy Pharmaceuticals' assets including TRULANCE in March 2019, and Takeda's EMA approval for Entyvio's subcutaneous formulation in August 2020. The report identifies North America as the leading regional market with a projected 41.7% value share by 2031, followed by Europe at 30.1%.PR NewswireColonoscopy Bowel Preparation Drugs Market to Surpass US$ 2.4 Billion, Globally, by the End of 2027 - Coherent Market InsightsAccording to Coherent Market Insights, the global colonoscopy bowel preparation drugs market was valued at US$ 1,574.9 million in 2018 and is expected to grow at a CAGR of 4.9% to surpass US$ 2.4 billion by 2027, driven by rising prevalence of colorectal cancer. Key market players have been pursuing growth strategies including product launches and acquisitions; notably, Bausch Health Companies Inc. acquired certain assets of Synergy Pharmaceuticals Inc. in February 2019 to expand its gastrointestinal portfolio, and Norgine B.V. entered an exclusive license and distribution agreement with Faes Farma S.A. in February 2020 for PLENVU in Latin America.PharmasalmanacAdvances in the Oral Delivery of PeptidesLipid-based technology offers a promising approach for oral delivery of peptides, a goal pursued by both emerging and major pharmaceutical companies. Oral peptide delivery faces significant challenges including hydrophilicity, susceptibility to digestive enzymes in the GI tract, and the need to traverse the mucosal layer and tight junctions. Companies including Novo Nordisk (which received FDA approval for oral semaglutide in 2019), along with Allergan, Synergy Pharmaceuticals, and specialized developers such as Chiasma, Entrega, Emisphere, and Enteris Biopharma are employing various strategies including excipients, encapsulation, and lipid-based formulations to address these challenges.PR NewswireSHAREHOLDER ALERT: Pomerantz Law Firm Reminds Shareholders with Losses on their Investment in Synergy Pharmaceuticals, Inc. of Class Action Lawsuit and Upcoming Deadline - SGYPPomerantz LLP filed a securities class action lawsuit on April 9, 2019 in U.S. District Court against Synergy Pharmaceuticals, Inc. and three of its current and former officers, alleging they made materially false and misleading statements about the company's lead drug TRULANCE and its $300 million senior secured loan from CRG Partners III L.P. The complaint covers shareholders who purchased Synergy securities between September 5, 2017 and October 25, 2018, alleging defendants concealed that TRULANCE had underperformed and that the company faced covenant compliance issues with the CRG loan. On October 25, 2018, the company revealed these issues and the failure of its strategic review process, causing Synergy's stock to decline approximately 69% to $0.43 per share, damaging investors.PR NewswireSynergy Pharmaceuticals Announces Completion of Sale to Bausch HealthSynergy Pharmaceuticals confirmed the completion of its asset sale to Bausch Health Companies, transferring all rights to TRULANCE and related intellectual property. This transaction follows Synergy's voluntary Chapter 11 bankruptcy filing in December 2018 aimed at addressing debt obligations through an orderly sale process.PR NewswireBausch Health Completes Acquisition Of Certain Assets Of Synergy Pharmaceuticals Inc.Bausch Health Companies Inc. announced on March 6, 2019 that it has completed the acquisition of certain assets of Synergy Pharmaceuticals Inc. for approximately $195 million in cash, plus the assumption of certain liabilities, following approval by the U.S. Bankruptcy Court for the Southern District of New York. The acquisition includes Synergy's flagship product TRULANCE® (plecanatide) for chronic idiopathic constipation and irritable bowel syndrome with constipation, as well as the investigational compound dolcanatide. The acquired assets will be integrated into Bausch Health's Salix Pharmaceuticals gastroenterology business, which the company expects will organically grow its core operations in 2019.PR NewswireSynergy Pharmaceuticals Receives Court Approval for the Sale of Its Assets to Bausch HealthSynergy Pharmaceuticals received court approval for the sale of its assets, including the TRULANCE® drug and related intellectual property, to Bausch Health Companies Inc. The transaction is expected to close on or about March 5, 2019, following Synergy's voluntary Chapter 11 bankruptcy filing in December 2018. This development resolves the previous agreement between the two entities to facilitate Synergy's debt restructuring.PR NewswireBausch Health to Acquire Certain Assets of Synergy Pharmaceuticals Inc.Bausch Health Companies Inc. was selected as the successful bidder to acquire certain assets of bankrupt Synergy Pharmaceuticals Inc. for approximately $195 million in cash plus assumption of certain liabilities, with a court hearing scheduled for March 1, 2019. Synergy had filed for Chapter 11 bankruptcy in December 2018 and conducted the sale process pursuant to Section 363 of the Bankruptcy Code. The acquisition will add Synergy's flagship product TRULANCE and investigational compound dolcanatide to Bausch Health's gastroenterology portfolio under its Salix Pharmaceuticals business.PR NewswireSynergy Pharmaceuticals Confirms Bausch Health as Successful Bidder for Its Business AssetsSynergy Pharmaceuticals Inc. has confirmed that Bausch Health Companies Inc. has been designated as the successful bidder for its assets, including the commercial drug TRULANCE and related intellectual property, following Chapter 11 bankruptcy proceedings initiated on December 12, 2018. The auction scheduled for February 26, 2019 was cancelled after no party submitted a higher and better bid than the previously announced agreement with Bausch Health. The transaction is expected to receive Bankruptcy Court approval on March 1, 2019, pending the completion of standard closing conditions.PR NewswireInvestor Alert: Kaplan Fox Announces Investigation Of Synergy Pharmaceuticals Inc.Kaplan Fox & Kilsheimer LLP announced an investigation into Synergy Pharmaceuticals Inc. on behalf of investors who purchased company securities between September 7, 2017 and October 25, 2018, with a complaint filed in the U.S. District Court for the Eastern District of New York against certain Synergy executives. The complaint alleges that Synergy failed to meet a minimum revenue covenant of $61 million for its drug TRULANCE, projecting only $42-47 million in sales for 2018, and disclosed potential default risks on a $300 million senior secured loan from CRG Partners III L.P., facing prepayment penalties of $38-51 million. Following the October 25, 2018 disclosures, Synergy's stock price fell 69% to $0.43 per share.